Malignant Neoplasm

Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS… (full text at CIViC)

PMID 21642865 · Lee et al., 2011 · Open in CIViC

In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the tar… (full text at CIViC)

PMID 20940188 · Sequist et al., 2010 · Open in CIViC

In a stage IV lung adenocarcinoma patient, ALK I1171N was associated with acquired resistance to crizotinib monotherapy. An ALK gene rearrangement had been previously identified and was associated wi… (full text at CIViC)

PMID 27565911 · Johnson et al., 2016 · Open in CIViC

A case study of a 58 year old woman with ALK-rearranged NSCLC found the resistance mutation L1196M following treatment with crizotinib and alectinib. Treatment with ceritinib resulted in tumour regres… (full text at CIViC)

PMID 29796191 · Makuuchi et al., 2018 · Open in CIViC

In a prospective study (NCT01283516) of 130 cancer patients, non-small cell lung cancer patients (n=2) harboring a L1196M mutation in the ALK portion of the ALK rearrangement were associated with a 50… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC)

PMID 35233056 · Mansfield et al., 2022 · Open in CIViC

BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

A case of metastatic renal cell carcinoma (RCC) is reported with a novel translocation t(X;9)(p11.23;p13.3) and RNA-seq identification of a putative corresponding fusion: VCP::TFE3. TFE3 fusion positi… (full text at CIViC)

PMID 36695651 · Kuentz et al., 2023 · Open in CIViC

Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.

PMID 25973082 · Tsai et al., 2015 · Open in CIViC

Tumor samples from the phase III trial of FOLFOX4
bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2).

PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC

A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC)

PMID 25947646 · Santos et al., 2015 · Open in CIViC

In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression.

PMID 29747600 · Martini et al., 2018 · Open in CIViC

Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC)

PMID 27817944 · Miles et al., 2017 · Open in CIViC

In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC)

PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC

Nude mice were injected with VEGF165b-transfected LS174t colon cancer cells or control LS174t cells and treated with bevacizumab. VEGF165b expressing tumors grew faster than those not expressing VEGF1… (full text at CIViC)

PMID 18349829 · Varey et al., 2008 · Open in CIViC

Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC)

PMID 21787417 · Harmon et al., 2011 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In this 2017 study, the authors analyzed molecular features of 26 pediatric spindle cell and sclerosing rhabdomyosarcoma (SRMS) cases. The cohort included 11 congenital/infantile patients (age 0–1 yea… (full text at CIViC)

PMID 26501226 · Alaggio et al., 2016 · Open in CIViC

In this 2015 study, the authors analyzed 26 pediatric spindle cell and sclerosing rhabdomyosarcoma (SRMS) cases, including 11 congenital/infantile cases, using a combination of RNA sequencing, FISH, t… (full text at CIViC)

PMID 26501226 · Alaggio et al., 2016 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identifi… (full text at CIViC)

PMID 7915601 · Gnarra et al., 1994 · Open in CIViC

Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH… (full text at CIViC)

PMID 7915601 · Gnarra et al., 1994 · Open in CIViC

Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identifi… (full text at CIViC)

PMID 7915601 · Gnarra et al., 1994 · Open in CIViC

A case report revealed a 7 month old male infant of Bangladesh ethnicity with a novel homozygous VHL germline missense (c.376G>A; p.Asp126Asn) mutation with congenital polycythemia and dramatically el… (full text at CIViC)

PMID 24729484 · Sarangi et al., 2014 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

In a 54 year old male patient with sporadic renal cell carcinoma, VHL c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative… (full text at CIViC)

PMID 10408776 · Gallou et al., 1999 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identifi… (full text at CIViC)

PMID 7915601 · Gnarra et al., 1994 · Open in CIViC

Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identifi… (full text at CIViC)

PMID 7915601 · Gnarra et al., 1994 · Open in CIViC

In a study of 31 kidney tumor from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with… (full text at CIViC)

PMID 7591282 · Bailly et al., 1995 · Open in CIViC

In a study of 31 kidney tumor from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with… (full text at CIViC)

PMID 7591282 · Bailly et al., 1995 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC